Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation

Completed · Phase 3

Conditions studied: Atrial Fibrillation

In brief

This study is designed to determine the safety of RSD1235 in patients with atrial fibrillation.

Key facts

Study ID

NCT00281554

Run by

Astellas Pharma Inc

People needed

254

Starts

2005-10-01

Expected to finish

2007-01-01

Last updated by the study team

2008-04-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject must have symptomatic AF
• Subject must have adequate anticoagulant therapy

You may not qualify if…

• Subject may not have Class IV congestive heart failure.
• Subject may not have uncorrected electrolyte imbalance.

Where it is running

• Study site — Huntsville, Alabama, United States
• Study site — Atlanta, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Oak Lawn, Illinois, United States
• Study site — Boston, Massachusetts, United States
• Study site — Lansing, Michigan, United States
• Study site — Austin, Texas, United States
• Study site — San Antonio, Texas, United States
• Study site — Richmond, Virginia, United States
• Study site — Marshfield, Wisconsin, United States
• Study site — Buenos Aires, Argentina
• Study site — Buenos Aires, Argentina
• Study site — Buenos Aires, Argentina
• Study site — Buenos Aires, Argentina
• Study site — Buenos Aires, Argentina
• Study site — Corrientes, Argentina
• Study site — De Buenos Aires, Argentina
• Study site — Rosario, Argentina
• Study site — Tulunaw, Argentina
• Study site — Calgary, Alberta, Canada
• Study site — Ottawa, Ontario, Canada
• Study site — Montreal, Quebec, Canada
• Study site — Montreal, Quebec, Canada
• Study site — Terrebonne, Quebec, Canada
• Study site — Aalborg, Denmark

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.